$522 Million is the total value of NEXTHERA CAPITAL LP's 56 reported holdings in Q3 2018. The portfolio turnover from Q2 2018 to Q3 2018 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| AVRO | Exit | Avrobio Inc | $0 | – | -10,000 | -100.0% | -0.04% | – |
| TGTX | Exit | TG Therapeutics Inccall | $0 | – | -50,000 | -100.0% | -0.10% | – |
| KNSA | Exit | Kiniksa Pharmaceuticals Ltd | $0 | – | -39,180 | -100.0% | -0.10% | – |
| CRBP | Exit | Corbus Pharmaceuticals Holding | $0 | – | -134,280 | -100.0% | -0.10% | – |
| VSAR | Exit | Versartis Inc | $0 | – | -500,000 | -100.0% | -0.16% | – |
| ARPO | Exit | Aerpio Pharmaceuticals Inc | $0 | – | -298,873 | -100.0% | -0.19% | – |
| SLGL | Exit | Sol-Gel Technologies Ltd | $0 | – | -515,373 | -100.0% | -0.62% | – |
| CORT | Exit | Corcept Therapeutics Inc | $0 | – | -335,177 | -100.0% | -0.82% | – |
| SGEN | Exit | Seattle Genetics Inc | $0 | – | -102,187 | -100.0% | -1.05% | – |
| ESPR | Exit | Esperion Therapeutics Inc | $0 | – | -287,300 | -100.0% | -1.74% | – |
| SAGE | Exit | Sage Therapeutics Inc | $0 | – | -79,080 | -100.0% | -1.92% | – |
| SGMO | Exit | Sangamo Therapeutics Inc | $0 | – | -1,066,914 | -100.0% | -2.35% | – |
| CLLS | Exit | Cellectis SAsponsored ads | $0 | – | -548,212 | -100.0% | -2.40% | – |
| ALXN | Exit | Alexion Pharmaceuticals Inc | $0 | – | -132,623 | -100.0% | -2.55% | – |
| PCRX | Exit | Pacira Pharmaceuticals Inc/DE | $0 | – | -566,508 | -100.0% | -2.81% | – |
| TSRO | Exit | TESARO Inc | $0 | – | -433,500 | -100.0% | -2.98% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Insmed Inc | 13 | Q2 2019 | 10.0% |
| Global Blood Therapeutics Inc | 11 | Q2 2019 | 6.2% |
| Shire PLC | 9 | Q1 2018 | 13.6% |
| Immunomedics Inc | 9 | Q2 2019 | 7.8% |
| Allergan PLC | 8 | Q2 2019 | 7.6% |
| FibroGen Inc | 8 | Q3 2018 | 3.0% |
| Abeona Therapeutics Inc | 8 | Q3 2018 | 2.1% |
| Pfizer Inc | 7 | Q2 2017 | 19.1% |
| Seattle Genetics Inc | 7 | Q2 2018 | 5.7% |
| Mylan NV | 7 | Q2 2019 | 6.5% |
View NEXTHERA CAPITAL LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| CATALYST BIOSCIENCES, INC. | February 14, 2019 | 376,010 | 3.1% |
| CHIASMA, INC | February 14, 2019 | 1,066,439 | 4.4% |
| ONCOSEC MEDICAL IncSold out | February 14, 2019 | 0 | 0.0% |
| Zosano Pharma Corp | April 05, 2018 | 700,000 | 5.9% |
| VistaGen Therapeutics, Inc. | May 24, 2016 | 138,132 | 1.8% |
View NEXTHERA CAPITAL LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2019-08-14 |
| 13F-HR | 2019-05-15 |
| 13F-HR | 2019-02-14 |
| SC 13G/A | 2019-02-14 |
| SC 13G/A | 2019-02-14 |
| SC 13G/A | 2019-02-14 |
| SC 13G | 2018-11-26 |
| 13F-HR | 2018-11-14 |
| 13F-HR | 2018-08-14 |
| SC 13G | 2018-06-11 |
View NEXTHERA CAPITAL LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.